Dipeptidyl peptidase 4(DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Saxagliptin is a substrate of CYP3A4/5 enzymes while other DPP4 inhibitors such as sita
Symplicity-3 hypertension(HTN)was a recently completed clinical trial that was assumed to be the basis for the approved use of renal artery denervation for the